Showing results (1-10 of 186) with videos related to
Sort By:
Pageof 19
Cells|August 12, 2022
Bone Disease in Multiple Myeloma: Biologic and Clinical ImplicationsZachary S Bernstein, E Bridget Kim, Noopur RajeCancers|May 17, 2020
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?E Bridget Kim, Andrew J Yee, Noopur Raje[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
Current management and emerging treatment strategies for multiple myelomaMatthew Lei, E Bridget Kim, Andrew Branagan, et al.Leukemia|November 30, 2019
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?Mattia D'Agostino, Noopur RajeThe Oncologist|April 16, 2011
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the futureSamantha Pozzi, Noopur RajeCurrent Opinion in Molecular Therapeutics|October 2, 2010
Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone lossNoopur Raje, Sonia ValletCancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 6, 2011
Bone anabolic agents for the treatment of multiple myelomaSonia Vallet, Noopur RajeJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2020
How We Approach Smoldering Multiple MyelomaNoopur Raje, Andrew J YeeHematology. American Society of Hematology. Education Program|December 10, 2021
Minimal residual disease in multiple myeloma: why, when, whereAndrew J Yee, Noopur RajeCurrent Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C AndersonPageof 19